Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37465
Title: | Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial | Authors: | Ono, Masafumi Onuma, Yoshinobu Kawashima, Hideyuki Hara, Hironori Gao, Chao Wang, Rutao O'Leary, Neil BENIT, Edouard Janssens, Luc Ferrario, Maurizio Zurakowski, Aleksander Dominici, Marcello Huber, Kurt Buszman, Pawel Garg, Scot Wykrzykowska, Joanna J. Piek, Jan J. Juni, Peter Hamm, Christian Windecker, Stephan VRANCKX, Pascal Deliargyris, Efthymios N. Bhatt, Deepak L. Storey, Robert F. Valgimigli, Marco Serruys, Patrick W. |
Issue Date: | 2022 | Publisher: | WILEY | Source: | CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, | Status: | Early view | Abstract: | Background Several studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events. Aims We aimed to investigate the association between PPI and clinical outcomes in patients treated with ticagrelor monotherapy or conventional antiplatelet therapy after percutaneous coronary intervention (PCI). Methods This is a subanalysis of the randomized GLOBAL LEADERS trial, comparing the experimental antiplatelet arm (23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy [DAPT]) with the reference arm (12-month aspirin monotherapy following 12-month DAPT) after PCI. Patient-oriented composite endpoints (POCEs: all-cause mortality, myocardial infarction, stroke, or repeat revascularization) and its components were assessed stratified by PPI use as a time-dependent covariate in patients with the experiment or reference antiplatelet arm. Results Among 15,839 patients, 2115 patients (13.5%) experienced POCE at 2 years. In the reference arm, the use of PPIs was independently associated with POCE (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 1.12-1.44) and its individual components, whereas it was not in the experimental arm (HR: 1.04; 95% CI: 0.92-1.19; p(interaction) = 0.035). During the second-year follow-up, patients taking aspirin with PPIs had a significantly higher risk of POCE compared to those on aspirin without PPIs (HR: 1.57; 95% CI: 1.27-1.94), whereas the risk did not differ significantly irrespective of PPI in ticagrelor monotherapy group (HR: 1.03; 95% CI: 0.83-1.28; p(interaction) = 0.008). Conclusions In contrast to conventional antiplatelet strategy, there were no evidence suggesting the interaction between ticagrelor monotherapy and PPIs on increased cardiovascular events, which should be confirmed in further studies. Clinical Trial Registration URL: | Notes: | Serruys, PW (corresponding author), Natl Univ Ireland Galway NUIG, Intervent Med & Innovat, Galway, Ireland. patrick.w.j.c.serruys@gmail.com |
Keywords: | drug interaction;dual antiplatelet therapy;percutaneous coronary intervention;proton pump inhibitor;ticagrelor monotherapy | Document URI: | http://hdl.handle.net/1942/37465 | ISSN: | 1522-1946 | e-ISSN: | 1522-726X | DOI: | 10.1002/ccd.30217 | ISI #: | WOS:000789604300001 | Rights: | 2022 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention_ Insights from the GLOBAL LEADERS trial.pdf | Published version | 1.39 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.